menu
Main Data: 31/12 Year 2017 | |
Consolidated income statement (international practice in accordance with IAS/IFRS) | Millions/Euro |
– total revenue | 1,444.73 |
– industrial gross profit | 541.27 |
– total operating cost | 376.05 |
– operating profit | 165.22 |
– net financial expense | 15.92 |
– profit attributable to equity holders of the parent | 85.59 |
Consolidated balance sheet | Millions/Euro |
– working capital | 26.82 |
– non-current assets | 501.28 |
– provision for severance indemnities and other provisions | -87.52 |
– net debt | -50.05 |
– equity pertaining to the group and minority interests | 390.53 |
Other information | Millions/Euro |
– depreciation and amortization | 42.46 |
– R & D costs | 53.99 |
Euro | |
Dividend per share | 1.60 |
No. | |
Employees | 5,448 |
Euro | |
Share capital | 20,415,200 |
Net Sales By Sector: Year 2017 | ||
Millions/Euro | ||
tea, food & other | 727.10 | 50.3% |
pharmaceutical | 565.87 | 39.2% |
tobacco packaging | 151.76 | 10.5% |
Total | 1,444.73 | 100.0% |
Net Sales by Country: Year 2017 | ||
Millions/Euro | ||
E.U. (excluding Italy) | 449.56 | 31.1% |
Other European countries | 118.81 | 8.2% |
North America | 247.00 | 17.1% |
Asia & Middle East | 312.30 | 21.6% |
Other countries | 151.82 | 10.5% |
Total exports | 1,279.49 | 88.5% |
Italy | 165.24 | 11.5% |
Total | 1,444.73 | 100.0% |
Main Data: 30/06 Year 2017 | |
Consolidated income statement (international practice in accordance with IAS/IFRS) | Millions/Euro |
– total revenue | 654.6 |
– industrial gross profit | 252.7 |
– total operating cost | 190.0 |
– operating profit | 62.7 |
– net financial expense | 7.5 |
– profit attributable to equity holders of the parent | 31.9 |
Consolidated balance sheet | Millions/Euro |
– working capital | 54.7 |
– non-current assets | 469.4 |
– provision for severance indemnities and other provisions | -70.1 |
– net debt | -221.8 |
– equity pertaining to the group and minority interests | 232.2 |
Other information | Millions/Euro |
– depreciation and amortization | 19.8 |
– R & D costs | 26.7 |
No. | |
Employees | 5,382 |
Euro | |
Share capital | 20,415,200 |